Envoy Medical Q3 net loss narrows 32% to $5.24 million
COCH•Envoy Medical’s third-quarter 2026 net loss attributable to common stockholders narrowed 32% year over year to $5.24 million. Revenue rose 57% to $66,000, and cash totaled $14.57 million at September 30.
1. Quarterly results and trial
Envoy Medical reported a third-quarter net loss attributable to common stockholders of $5.24 million, down 32% year over year, and net revenue of $66,000, up 57%. Cash totaled $14.57 million at September 30, 2026. After quarter-end, all 56 Acclaim trial patients passed six-month follow-up, and the company submitted the second module of its FDA approval application. All Stage 2 participants are expected to complete 12-month data collection by early second-quarter 2027, with final submission planned months later.
